NEW YORK, August 17, 2017 /PRNewswire/ --
If you want a Stock Review on RDUS, ABEO, CBIO, or CERC then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. On Wednesday, the NASDAQ Composite ended the day at 6,345.11, up 0.19%; the Dow Jones Industrial Average edged 0.12% higher, to finish at 22,024.87; and the S&P 500 closed at 2,468.11, marginally gaining 0.14%. Gains were broad based as seven out of nine sectors finished the trading session in green. DailyStockTracker.com has initiated research reports on the following Biotechnology stocks: Radius Health Inc. (NASDAQ: RDUS), Abeona Therapeutics Inc. (NASDAQ: ABEO), Catalyst Biosciences Inc. (NASDAQ: CBIO), and Cerecor Inc. (NASDAQ: CERC). Daily Stock Tracker published comprehensive and free research reports on these stocks today at:
Waltham, Massachusetts headquartered Radius Health Inc.'s stock finished Wednesday's session 4.41% higher at $36.43 with a total trading volume of 1.10 million shares. The stock has gained 10.80% over the past three months. The Company's shares are trading below their 50-day moving average by 14.14%. Moreover, shares of Radius Health, which develops and sells therapeutics in the areas of osteoporosis, oncology, and endocrine diseases primarily in the US, have a Relative Strength Index (RSI) of 38.44. RDUS complete research report is just a click away and free at:
Shares in Dallas, Texas-based Abeona Therapeutics Inc. rose 4.94%, ending yesterday's session at $8.50. A total volume of 683,251 shares was traded, which was above its three months average of 486.96 thousand shares. The stock has gained 42.86% in the previous three months, 116.28% over the past twelve months, and 75.26% on an YTD basis. The Company's shares are trading above their 50-day and 200-day moving averages by 17.21% and 43.67%, respectively. Moreover, shares of Abeona Therapeutics, which focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, have an RSI of 58.29.
On July 18th, 2017, research firm Maxim Group reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $14 a share to $17 a share. The complimentary report on ABEO can be downloaded at:
On Wednesday, South San Francisco, California headquartered Catalyst Biosciences Inc.'s stock saw an increase of 2.08%, to close the day at $3.43. A total volume of 73,094 shares was traded. The stock is trading below its 50-day moving average by 19.29%. Additionally, shares of Catalyst Biosciences, which focuses on developing medicines to address hematology indications, have an RSI of 29.15. Sign up for your complimentary research report on CBIO at:
Shares in Baltimore, Maryland headquartered Cerecor Inc. ended the day 0.38% lower at $0.58. A total volume of 164,504 shares was traded. The Company's shares are trading below their 50-day moving average by 13.03%. Furthermore, shares of Cerecor, which develops drugs to treat patients with neurological and psychiatric disorders, have an RSI of 42.61. Get free access to your research report on CERC at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA